Abstract
The therapeutic potential of targeting p21-Activated Kinases (PAK1 – 6) for the treatment of cancer has recently gained traction in the biotech industry. Many pharmaceutically-viable ATP competitive inhibitors have been through different stages of pre-clinical development with only a single compound evaluated in human trails (PF-3758309). The best studied functional roles of PAK proteins are control of cell adhesion and migration. PAK proteins are known downstream effectors of Ras signaling with PAK expression elevated in cancer (pancreatic, colon, breast, lung and other solid tumors). In addition altered PAK expression is a confirmed driver of this disease, especially in tumors harboring oncogenic Ras. However, there are very few examples of gain-of-function PAK mutations, as a majority of the cancer types have elevated PAK expression due to gene amplification or transcriptional modifications. There is a substantial number of known substrates affected by this aberrant PAK activity. One particular substrate, β-catenin, has garnered interest given its importance in both normal and cancer cell development. These data place PAK proteins between two major signaling pathways in cancer (Ras and β -catenin), making therapeutic targeting of PAKs an intriguing approach for the treatment of a broad array of oncological malignancies.
Keywords: Inhibitors, oncology, p21-activated kinase, Ras, Wnt; β-catenin.
Anti-Cancer Agents in Medicinal Chemistry
Title:Therapeutic Potential of Targeting PAK Signaling
Volume: 16 Issue: 1
Author(s): William Senapedis, Marsha Crochiere, Erkan Baloglu and Yosef Landesman
Affiliation:
Keywords: Inhibitors, oncology, p21-activated kinase, Ras, Wnt; β-catenin.
Abstract: The therapeutic potential of targeting p21-Activated Kinases (PAK1 – 6) for the treatment of cancer has recently gained traction in the biotech industry. Many pharmaceutically-viable ATP competitive inhibitors have been through different stages of pre-clinical development with only a single compound evaluated in human trails (PF-3758309). The best studied functional roles of PAK proteins are control of cell adhesion and migration. PAK proteins are known downstream effectors of Ras signaling with PAK expression elevated in cancer (pancreatic, colon, breast, lung and other solid tumors). In addition altered PAK expression is a confirmed driver of this disease, especially in tumors harboring oncogenic Ras. However, there are very few examples of gain-of-function PAK mutations, as a majority of the cancer types have elevated PAK expression due to gene amplification or transcriptional modifications. There is a substantial number of known substrates affected by this aberrant PAK activity. One particular substrate, β-catenin, has garnered interest given its importance in both normal and cancer cell development. These data place PAK proteins between two major signaling pathways in cancer (Ras and β -catenin), making therapeutic targeting of PAKs an intriguing approach for the treatment of a broad array of oncological malignancies.
Export Options
About this article
Cite this article as:
Senapedis William, Crochiere Marsha, Baloglu Erkan and Landesman Yosef, Therapeutic Potential of Targeting PAK Signaling, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (1) . https://dx.doi.org/10.2174/1871520615666150617111414
DOI https://dx.doi.org/10.2174/1871520615666150617111414 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Role of Oxidative Stress Response Elements and Antioxidants in Prostate Cancer Pathobiology and Chemoprevention -- A Mechanistic Approach
Current Medicinal Chemistry Antimicrobial Agents Deriving from Indigenous Plants
Recent Patents on Food, Nutrition & Agriculture Radiosensitizing Effect of Electrochemotherapy: A Systematic Review of Protocols and Efficiency
Current Drug Targets Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Biotransformation in Conceptal Toxicity of Drugs and Other Chemicals
Current Pharmaceutical Design The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents
Letters in Drug Design & Discovery ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Evolution of Ipsilateral Head and Neck Radiotherapy
Current Cancer Therapy Reviews Treatment Related Morbidity in Cervical Cancer
Current Women`s Health Reviews Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents
Anti-Cancer Agents in Medicinal Chemistry Phytocompounds from the Medicinal and Dietary Plants: Multi-target Agents for Cervical Cancer Prevention and Therapy
Current Medicinal Chemistry Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery Hyperpolarized 13Carbon MR
Current Pharmaceutical Biotechnology Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets